A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret prostate-specific antigen (PSA) test results compared to existing models.

PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Results of a study led by VHIO’s Prostate Cancer Group suggest that treatment with CDK4/6 inhibitors followed by senloytic therapies and PARP inhibitors could improve outcomes and combat cancer drug ...

Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, ...